Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 2/20 | 0.74 |
| ▸ | NADK | O95544 | 2/20 | 0.73 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.71 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.71 |
| ▸ | SRC | P12931 | 1/20 | 0.71 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.71 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.71 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.71 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.68 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.68 |
| ▸ | IMPDH1 | P20839 | 3/20 | 0.68 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.67 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.67 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.67 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Triphosphate SCHEMBL811698 | 0.99 | ADH1A (0.75) | ADH1ANADKP2RY1P2RY2SRC | |
| Adenosine Phosphate SCHEMBL160972 | 0.94 | P2RY1 (0.75) | ADH1ANADKP2RY1P2RY2SRC | |
| Adenosine Phosphate SCHEMBL27419541 | 0.94 | P2RY1 (0.75) | ADH1ANADKP2RY1P2RY2SRC | |
| Adenosine Triphosphate SCHEMBL811713 | 0.93 | P2RY1 (0.72) | ADH1ANADKP2RY1P2RY2SRC | |
| Adenosine Diphosphate SCHEMBL11326192 | 0.92 | ADH1A (0.64) | ADH1ANADKP2RY1P2RY2SRC | |
| Niacinamide SCHEMBL28249016 | 0.89 | ADH1A (0.66) | ADH1ANADKP2RY1P2RY2SRC | |
| SCHEMBL811714 | 0.89 | P2RY1 (0.63) | ADH1ANADKP2RY1P2RY2SRC | |
| SCHEMBL810819 | 0.89 | P2RY1 (0.69) | ADH1ANADKP2RY1P2RY2SRC | |
| Adenosine Phosphate SCHEMBL810818 | 0.88 | DNPH1 (0.75) | ADH1AP2RY1P2RY2SRCP2RX1 | |
| Niacinamide SCHEMBL14861027 | 0.87 | ADH1A (0.84) | ADH1ANADKP2RY1P2RY2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005017134-A2 | ISOZYME OF AUTOCLAVABLE SUPEROXIDE DISMUTASE (SOD) DERIVED FROM CURCUMA LONGA L | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-02-24 | — | — | WO | claimed |
| US-20030064494-A1 | Novel isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD and use of the said SOD in cosmetic, food, and pharmaceutical compositions | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2003-04-03 | — | — | US | claimed |
| US-6485950-B1 | Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2002-11-26 | — | — | US | claimed |
| CN-115624563-A | Application of nicotinamide mononucleotide to preparation of medicine or health-care product for preventing or treating occupational silicosis | 四川大学 | 2023-01-20 | — | — | CN | disclosed |
| US-20180147186-A1 | BENDAMUSTINE DERIVATIVES AND METHODS OF USING SAME | IGNYTA, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-9913827-B2 | Bendamustine derivatives and methods of using same | IGNYTA, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170182008-A1 | BENDAMUSTINE DERIVATIVES AND METHODS OF USING SAME | IGNYTA, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-9630926-B2 | Bendamustine derivatives and methods of using same | IGNYTA, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160289198-A1 | BENDAMUSTINE DERIVATIVES AND METHODS OF USING SAME | IGNYTA, INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-9452988-B2 | Bendamustine derivatives and methods of using same | IGNYTA, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| WO-2016131320-A1 | USE OF NADPH IN PREPARING MEDICINES FOR TREATMENT OF HEART DISEASES | 苏州人本药业有限公司 | 2016-08-25 | — | — | WO | disclosed |
| US-20020142006-A1 | Chimeric nontoxic mutants of enterotoxins as mucosal adjuvants for cell-mediated or humoral immunity | MCGHEE JERRY R (US) | 2002-10-03 | — | — | US | disclosed |
| WO-2001070257-A1 | CHIMERIC NONTOXIC MUTANTS OF ENTEROTOXINS AS MUCOSAL ADJUVANTS FOR CELL-MEDIATED OR HUMORAL IMMUNITY | UAB RESEARCH FOUNDATION (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-0531447-B1 | COMPOSITIONS AND METHODS FOR MODULATING RNA ACTIVITY THROUGH MODIFICATION OF THE 5' CAP STRUCTURE OF RNA | ISIS PHARMACEUTICALS INC (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5643780-A | CONTROLLING PROTEIN EXPRESSION IN CELLS | ISIS PHARMACEUTICALS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0531447-A4 | COMPOSITIONS AND METHODS FOR MODULATING RNA ACTIVITY THROUGH MODIFICATION OF THE 5' CAP STRUCTURE OF RNA | — | 1993-08-11 | — | — | EP | disclosed |
| EP-0531447-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA ACTIVITY THROUGH MODIFICATION OF THE 5' CAP STRUCTURE OF RNA | ISIS PHARMACEUTICALS, INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| WO-1991017755-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA ACTIVITY THROUGH MODIFICATION OF THE 5' CAP STRUCTURE OF RNA | ISIS PHARMACEUTICALS, INC. (US) | 1991-11-28 | — | — | WO | disclosed |
| US-4614770-A | HYDROCYANATION OF CARBONYL, THIOCARBONYL OR IMINO GROUPS; POLYMERS BEARING PYRIDINE-NUCLEUS RING SUBSTITUTED BY CARBOXAMIDE GROUPS | ALLIED CORPORATION (US) | 1986-09-30 | — | — | US | disclosed |
| US-4614769-A | NADH2 mimics as chiral pseudohydrogenases | ALLIED CORPORATION (US) | 1986-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182008-A1 | BENDAMUSTINE DERIVATIVES AND METHODS OF USING SAME | FLT4, MET, FOLR2 | ADH1A 2078/4885NADK 1471/4885P2RY1 3763/4885 |
| US-20160289198-A1 | BENDAMUSTINE DERIVATIVES AND METHODS OF USING SAME | FLT4, MET, FOLR2 | ADH1A 2078/4885NADK 1471/4885P2RY1 3763/4885 |
| US-20180147186-A1 | BENDAMUSTINE DERIVATIVES AND METHODS OF USING SAME | FLT4, MET, FOLR2 | ADH1A 2078/4885NADK 1471/4885P2RY1 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.